Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359788 · ClinicalTrials.gov registry record · Phase 4
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 349
- Enrollment target
NCT00359788 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 349 participants.
The verdict
NCT00359788, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 349 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.
Interventions
- DRUG tiotropium
- DRUG Combivent (Ipratropium/Albuterol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2006-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359788
The ClinicalTrials.gov registry entry for NCT00359788 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tiotropium is the first listed.
NCT00359788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359788 about?
NCT00359788 is a clinical study titled "A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.". The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease ...
What is the current status of trial NCT00359788?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 349 participants. The study started on 2006-07.
What interventions are being tested in trial NCT00359788?
The interventions under investigation include: tiotropium (DRUG), Combivent (Ipratropium/Albuterol) (DRUG).
Who is sponsoring clinical trial NCT00359788?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.